Xconomy: Supercharged Herceptin Nears Pivot Point, as ImmunoGen, Roche Await Data on Breast Cancer "Smart Bomb"
Summary
Supercharged Herceptin Nears Pivot Point, as ImmunoGen, Roche Await Data on Breast Cancer “Smart Bomb” (Page 2 of 3) had partial or complete tumor shrinkage, according to a final analysis of 112 patients in a clinical trial.These are patients who failed to respond to the standard trastuzumab and a competing drug from GlaxoSmithKline called lapatinib (Tykerb).If this drug can show that it can shrink tumors for a high percentage of patients who have failed those other treatments, it could be enough for Roche to whip up an application for regulatory approval.When I stopped by his office a few weeks ago, Junius wouldn’t define for me how well T-DM1 must perform in the 100-patient study being presented in San Antonio.Clinical trials that showed the original trastuzumab worked for those women have been a boon to Roche’s bottom line.
Classifications
AskAI Classifications
LabelsLinked Companies
